Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Aurenar closes an oversubscribed $5.7M Seed round led by Go Red for Women Venture Fund™ and Solas BioVentures to advance its neuromodulation platform for stroke care in ICUs.
PRIVATEJul 28, 2026•1 day ago
Amount Raised
$5.7 Million
Round Type
Seed
Saint LouisBiotechnologyHealth CareMedicalMedical Device
Investors
Kaleida CapitalBjc HealthSolas Bio VenturesGo Red For Women Venture Fund™
Description
Aurenar has announced the close of a $5.7 million seed financing round. The round was co-led by the Go Red for Women Venture Fund™ and Solas BioVentures, with additional participation from BJC Health and Kaleida Capital. Funds will support advancements toward pivotal trials and regulatory submissions for their V-Link™ platform. This platform aims to transform stroke care and address critical conditions in ICU patients.
Company Information
Company
Aurenar
Location
Saint Louis, Missouri, United States
About
Aurenar is a developer of a non-invasive, single-use neuromodulation platform aimed at reducing life-threatening complications in intensive care unit (ICU) patients. Their V-Link™ platform utilizes transauricular vagus nerve stimulation (taVNS) to address inflammation associated with critical conditions like stroke. With breakthrough device designation from the FDA, Aurenar is focused on advancing its technology towards pivotal trials. Founded by experts from Washington University School of Medicine, the company aims to transform stroke care in ICUs.
Saint LouisBiotechnologyHealth CareMedicalMedical Device